ID   CDKL5_HUMAN             Reviewed;         960 AA.
AC   O76039; G9B9X4; Q14198; Q5H985; Q8IYC7; Q9UJL6;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   07-OCT-2020, sequence version 2.
DT   12-OCT-2022, entry version 210.
DE   RecName: Full=Cyclin-dependent kinase-like 5 {ECO:0000305};
DE            EC=2.7.11.22;
DE   AltName: Full=Serine/threonine-protein kinase 9;
GN   Name=CDKL5 {ECO:0000312|HGNC:HGNC:11411}; Synonyms=STK9;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=9721213; DOI=10.1006/geno.1998.5391;
RA   Montini E., Andolfi G., Caruso A., Buchner G., Walpole S.M., Mariani M.,
RA   Consalez G.G., Trump D., Ballabio A., Franco B.;
RT   "Identification and characterization of a novel serine-threonine kinase
RT   gene from the Xp22 region.";
RL   Genomics 51:427-433(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), INVOLVEMENT IN DEE2, CHROMOSOMAL
RP   TRANSLOCATION, AND VARIANT PRO-791.
RX   PubMed=12736870; DOI=10.1086/375538;
RA   Kalscheuer V.M., Tao J., Donnelly A., Hollway G., Schwinger E., Kuebart S.,
RA   Menzel C., Hoeltzenbein M., Tommerup N., Eyre H., Harbord M., Haan E.,
RA   Sutherland G.R., Ropers H.-H., Gecz J.;
RT   "Disruption of the serine/threonine kinase 9 gene causes severe X-linked
RT   infantile spasms and mental retardation.";
RL   Am. J. Hum. Genet. 72:1401-1411(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), ALTERNATIVE SPLICING, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=21748340; DOI=10.1007/s00439-011-1058-x;
RA   Williamson S.L., Giudici L., Kilstrup-Nielsen C., Gold W., Pelka G.J.,
RA   Tam P.P., Grimm A., Prodi D., Landsberger N., Christodoulou J.;
RT   "A novel transcript of cyclin-dependent kinase-like 5 (CDKL5) has an
RT   alternative C-terminus and is the predominant transcript in brain.";
RL   Hum. Genet. 131:187-200(2012).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 339-789.
RX   PubMed=8864140; DOI=10.1002/jlb.60.4.540;
RA   Krause S.W., Rehli M., Kreutz M., Schwarzfischer L., Paulauskis J.D.,
RA   Andreesen J.D.;
RT   "Differential screening leads to novel genetic markers of monocyte to
RT   macrophage maturation.";
RL   J. Leukoc. Biol. 60:540-545(1996).
RN   [6]
RP   INVOLVEMENT IN DEE2.
RX   PubMed=15492925; DOI=10.1086/426462;
RA   Weaving L.S., Christodoulou J., Williamson S.L., Friend K.L.,
RA   McKenzie O.L.D., Archer H., Evans J., Clarke A., Pelka G.J., Tam P.P.L.,
RA   Watson C., Lahooti H., Ellaway C.J., Bennetts B., Leonard H., Gecz J.;
RT   "Mutations of CDKL5 cause a severe neurodevelopmental disorder with
RT   infantile spasms and mental retardation.";
RL   Am. J. Hum. Genet. 75:1079-1093(2004).
RN   [7]
RP   INTERACTION WITH MECP2, FUNCTION, AUTOPHOSPHORYLATION, AND INVOLVEMENT IN
RP   DEE2.
RX   PubMed=15917271; DOI=10.1093/hmg/ddi198;
RA   Mari F., Azimonti S., Bertani I., Bolognese F., Colombo E., Caselli R.,
RA   Scala E., Longo I., Grosso S., Pescucci C., Ariani F., Hayek G.,
RA   Balestri P., Bergo A., Badaracco G., Zappella M., Broccoli V., Renieri A.,
RA   Kilstrup-Nielsen C., Landsberger N.;
RT   "CDKL5 belongs to the same molecular pathway of MeCP2 and it is responsible
RT   for the early-onset seizure variant of Rett syndrome.";
RL   Hum. Mol. Genet. 14:1935-1946(2005).
RN   [8]
RP   FUNCTION, AUTOPHOSPHORYLATION, SUBCELLULAR LOCATION, AND CHARACTERIZATION
RP   OF VARIANTS DEE2 PHE-152 AND SER-175.
RX   PubMed=16935860; DOI=10.1074/jbc.m606325200;
RA   Bertani I., Rusconi L., Bolognese F., Forlani G., Conca B., De Monte L.,
RA   Badaracco G., Landsberger N., Kilstrup-Nielsen C.;
RT   "Functional consequences of mutations in CDKL5, an X-linked gene involved
RT   in infantile spasms and mental retardation.";
RL   J. Biol. Chem. 281:32048-32056(2006).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-407 AND SER-761, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-407, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-407 AND SER-720, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-407, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-479 AND SER-720, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [14] {ECO:0007744|PDB:4BGQ}
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 1-303 IN COMPLEX WITH SYNTHETIC
RP   INHIBITOR, SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=29420175; DOI=10.1016/j.celrep.2017.12.083;
RA   Canning P., Park K., Goncalves J., Li C., Howard C.J., Sharpe T.D.,
RA   Holt L.J., Pelletier L., Bullock A.N., Leroux M.R.;
RT   "CDKL Family Kinases Have Evolved Distinct Structural Features and Ciliary
RT   Function.";
RL   Cell Rep. 22:885-894(2018).
RN   [15]
RP   VARIANTS DEE2 PHE-152 AND SER-175, AND VARIANT PRO-791.
RX   PubMed=15499549; DOI=10.1086/426460;
RA   Tao J., Van Esch H., Hagedorn-Greiwe M., Hoffmann K., Moser B., Raynaud M.,
RA   Sperner J., Fryns J.-P., Schwinger E., Gecz J., Ropers H.-H.,
RA   Kalscheuer V.M.;
RT   "Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5/STK9) gene
RT   are associated with severe neurodevelopmental retardation.";
RL   Am. J. Hum. Genet. 75:1149-1154(2004).
RN   [16]
RP   INVOLVEMENT IN DEE2.
RX   PubMed=15689447; DOI=10.1136/jmg.2004.026237;
RA   Scala E., Ariani F., Mari F., Caselli R., Pescucci C., Longo I., Meloni I.,
RA   Giachino D., Bruttini M., Hayek G., Zappella M., Renieri A.;
RT   "CDKL5/STK9 is mutated in Rett syndrome variant with infantile spasms.";
RL   J. Med. Genet. 42:103-107(2005).
RN   [17]
RP   VARIANT DEE2 ASN-72, AND VARIANT CYS-444.
RX   PubMed=16015284; DOI=10.1038/sj.ejhg.5201451;
RA   Evans J.C., Archer H.L., Colley J.P., Ravn K., Nielsen J.B., Kerr A.,
RA   Williams E., Christodoulou J., Gecz J., Jardine P.E., Wright M.J.,
RA   Pilz D.T., Lazarou L., Cooper D.N., Sampson J.R., Butler R., Whatley S.D.,
RA   Clarke A.J.;
RT   "Early onset seizures and Rett-like features associated with mutations in
RT   CDKL5.";
RL   Eur. J. Hum. Genet. 13:1113-1120(2005).
RN   [18]
RP   VARIANTS DEE2 LEU-180 AND ALA-793.
RX   PubMed=16611748; DOI=10.1136/jmg.2006.041467;
RA   Archer H.L., Evans J., Edwards S., Colley J., Newbury-Ecob R.,
RA   O'Callaghan F., Huyton M., O'Regan M., Tolmie J., Sampson J., Clarke A.,
RA   Osborne J.;
RT   "CDKL5 mutations cause infantile spasms, early onset seizures, and severe
RT   mental retardation in female patients.";
RL   J. Med. Genet. 43:729-734(2006).
RN   [19]
RP   VARIANT [LARGE SCALE ANALYSIS] HIS-368.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [20]
RP   VARIANTS [LARGE SCALE ANALYSIS] THR-374; GLN-574; ALA-734; PRO-791 AND
RP   GLY-1023 (ISOFORM 2).
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [21]
RP   VARIANTS DEE2 VAL-40; PRO-220 AND MET-718.
RX   PubMed=18790821; DOI=10.1093/brain/awn197;
RA   Bahi-Buisson N., Nectoux J., Rosas-Vargas H., Milh M., Boddaert N.,
RA   Girard B., Cances C., Ville D., Afenjar A., Rio M., Heron D.,
RA   N'guyen Morel M.A., Arzimanoglou A., Philippe C., Jonveaux P., Chelly J.,
RA   Bienvenu T.;
RT   "Key clinical features to identify girls with CDKL5 mutations.";
RL   Brain 131:2647-2661(2008).
RN   [22]
RP   VARIANTS DEE2 VAL-40 AND PRO-220, AND CHARACTERIZATION OF VARIANTS DEE2
RP   VAL-40 AND PRO-220.
RX   PubMed=17993579; DOI=10.1136/jmg.2007.053504;
RA   Rosas-Vargas H., Bahi-Buisson N., Philippe C., Nectoux J., Girard B.,
RA   N'Guyen Morel M.A., Gitiaux C., Lazaro L., Odent S., Jonveaux P.,
RA   Chelly J., Bienvenu T.;
RT   "Impairment of CDKL5 nuclear localisation as a cause for severe infantile
RT   encephalopathy.";
RL   J. Med. Genet. 45:172-178(2008).
RN   [23]
RP   VARIANTS DEE2 PRO-178; ILE-288 AND TYR-291.
RX   PubMed=18809835; DOI=10.1212/01.wnl.0000326592.37105.88;
RA   Elia M., Falco M., Ferri R., Spalletta A., Bottitta M., Calabrese G.,
RA   Carotenuto M., Musumeci S.A., Lo Giudice M., Fichera M.;
RT   "CDKL5 mutations in boys with severe encephalopathy and early-onset
RT   intractable epilepsy.";
RL   Neurology 71:997-999(2008).
RN   [24]
RP   VARIANT DEE2 THR-399.
RX   PubMed=19253388; DOI=10.1002/ajmg.a.32711;
RA   Sprovieri T., Conforti F.L., Fiumara A., Mazzei R., Ungaro C., Citrigno L.,
RA   Muglia M., Arena A., Quattrone A.;
RT   "A novel mutation in the X-linked cyclin-dependent kinase-like 5 (CDKL5)
RT   gene associated with a severe Rett phenotype.";
RL   Am. J. Med. Genet. A 149:722-725(2009).
RN   [25]
RP   VARIANTS DEE2 THR-72 AND ARG-127, AND VARIANTS PRO-791 AND CYS-923 (ISOFORM
RP   2).
RX   PubMed=19241098; DOI=10.1007/s10048-009-0177-1;
RA   Russo S., Marchi M., Cogliati F., Bonati M.T., Pintaudi M., Veneselli E.,
RA   Saletti V., Balestrini M., Ben-Zeev B., Larizza L.;
RT   "Novel mutations in the CDKL5 gene, predicted effects and associated
RT   phenotypes.";
RL   Neurogenetics 10:241-250(2009).
RN   [26]
RP   VARIANT DEE2 GLN-178.
RX   PubMed=23662938; DOI=10.1111/epi.12203;
RA   Kodera H., Kato M., Nord A.S., Walsh T., Lee M., Yamanaka G., Tohyama J.,
RA   Nakamura K., Nakagawa E., Ikeda T., Ben-Zeev B., Lev D., Lerman-Sagie T.,
RA   Straussberg R., Tanabe S., Ueda K., Amamoto M., Ohta S., Nonoda Y.,
RA   Nishiyama K., Tsurusaki Y., Nakashima M., Miyake N., Hayasaka K.,
RA   King M.C., Matsumoto N., Saitsu H.;
RT   "Targeted capture and sequencing for detection of mutations causing early
RT   onset epileptic encephalopathy.";
RL   Epilepsia 54:1262-1269(2013).
RN   [27]
RP   VARIANTS DEE2 TYR-145; GLN-178; PRO-182; GLU-207; TYR-581 AND CYS-858, AND
RP   VARIANT 855-SER--LYS-960 DEL.
RX   PubMed=23708187; DOI=10.1038/ng.2646;
RA   Carvill G.L., Heavin S.B., Yendle S.C., McMahon J.M., O'Roak B.J., Cook J.,
RA   Khan A., Dorschner M.O., Weaver M., Calvert S., Malone S., Wallace G.,
RA   Stanley T., Bye A.M., Bleasel A., Howell K.B., Kivity S., Mackay M.T.,
RA   Rodriguez-Casero V., Webster R., Korczyn A., Afawi Z., Zelnick N.,
RA   Lerman-Sagie T., Lev D., Moeller R.S., Gill D., Andrade D.M., Freeman J.L.,
RA   Sadleir L.G., Shendure J., Berkovic S.F., Scheffer I.E., Mefford H.C.;
RT   "Targeted resequencing in epileptic encephalopathies identifies de novo
RT   mutations in CHD2 and SYNGAP1.";
RL   Nat. Genet. 45:825-830(2013).
RN   [28]
RP   VARIANT DEE2 GLN-178.
RX   PubMed=24564546; DOI=10.1186/1471-2350-15-24;
RA   Zhao Y., Zhang X., Bao X., Zhang Q., Zhang J., Cao G., Zhang J., Li J.,
RA   Wei L., Pan H., Wu X.;
RT   "Clinical features and gene mutational spectrum of CDKL5-related diseases
RT   in a cohort of Chinese patients.";
RL   BMC Med. Genet. 15:24-24(2014).
RN   [29]
RP   VARIANT LEU-647.
RX   PubMed=25969726; DOI=10.1186/s13229-015-0017-0;
RA   Codina-Sola M., Rodriguez-Santiago B., Homs A., Santoyo J., Rigau M.,
RA   Aznar-Lain G., Del Campo M., Gener B., Gabau E., Botella M.P.,
RA   Gutierrez-Arumi A., Antinolo G., Perez-Jurado L.A., Cusco I.;
RT   "Integrated analysis of whole-exome sequencing and transcriptome profiling
RT   in males with autism spectrum disorders.";
RL   Mol. Autism 6:21-21(2015).
RN   [30]
RP   VARIANTS DEE2 TRP-178; MET-718 AND 726-SER--LYS-1030 DEL.
RX   PubMed=26993267; DOI=10.1136/jmedgenet-2015-103263;
RA   Trump N., McTague A., Brittain H., Papandreou A., Meyer E., Ngoh A.,
RA   Palmer R., Morrogh D., Boustred C., Hurst J.A., Jenkins L., Kurian M.A.,
RA   Scott R.H.;
RT   "Improving diagnosis and broadening the phenotypes in early-onset seizure
RT   and severe developmental delay disorders through gene panel analysis.";
RL   J. Med. Genet. 53:310-317(2016).
RN   [31]
RP   VARIANTS DEE2 LEU-196 AND ARG-994 (ISOFORM 2).
RX   PubMed=27864847; DOI=10.1002/humu.23149;
RG   Clinical Study Group;
RA   Parrini E., Marini C., Mei D., Galuppi A., Cellini E., Pucatti D.,
RA   Chiti L., Rutigliano D., Bianchini C., Virdo S., De Vita D., Bigoni S.,
RA   Barba C., Mari F., Montomoli M., Pisano T., Rosati A., Guerrini R.;
RT   "Diagnostic targeted resequencing in 349 patients with drug-resistant
RT   pediatric epilepsies identifies causative mutations in 30 different
RT   genes.";
RL   Hum. Mutat. 38:216-225(2017).
CC   -!- FUNCTION: Mediates phosphorylation of MECP2 (PubMed:15917271,
CC       PubMed:16935860). May regulate ciliogenesis (PubMed:29420175).
CC       {ECO:0000269|PubMed:15917271, ECO:0000269|PubMed:16935860,
CC       ECO:0000269|PubMed:29420175}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.22;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.22;
CC   -!- SUBUNIT: Interacts with MECP2. {ECO:0000269|PubMed:15917271}.
CC   -!- INTERACTION:
CC       O76039; Q08379: GOLGA2; NbExp=3; IntAct=EBI-1752465, EBI-618309;
CC       O76039; P40692: MLH1; NbExp=4; IntAct=EBI-1752465, EBI-744248;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:16935860}. Cytoplasm,
CC       cytoskeleton, cilium basal body {ECO:0000269|PubMed:29420175}.
CC       Cytoplasm, cytoskeleton, microtubule organizing center, centrosome
CC       {ECO:0000269|PubMed:29420175}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O76039-2; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O76039-1; Sequence=VSP_060755;
CC   -!- TISSUE SPECIFICITY: Expressed in brain, lung, kidney, prostate, ovary,
CC       placenta, pancreas and testis.
CC   -!- TISSUE SPECIFICITY: [Isoform 2]: Predominant transcript in brain.
CC       {ECO:0000269|PubMed:21748340}.
CC   -!- PTM: Autophosphorylated.
CC   -!- DISEASE: Note=Chromosomal aberrations involving CDKL5 are found in
CC       patients manifesting early-onset seizures and spams and psychomotor
CC       impairment. Translocation t(X;6)(p22.3;q14); translocation
CC       t(X;7)(p22.3;p15).
CC   -!- DISEASE: Developmental and epileptic encephalopathy 2 (DEE2)
CC       [MIM:300672]: A severe form of epilepsy characterized by seizures or
CC       spasms beginning in infancy. Patients with epileptic encephalopathy
CC       early infantile type 2 manifest features resembling Rett syndrome such
CC       as microcephaly, lack of speech development, stereotypic hand
CC       movements. However, DEE2 and Rett syndrome are considered two distinct
CC       entities. {ECO:0000269|PubMed:12736870, ECO:0000269|PubMed:15492925,
CC       ECO:0000269|PubMed:15499549, ECO:0000269|PubMed:15689447,
CC       ECO:0000269|PubMed:15917271, ECO:0000269|PubMed:16015284,
CC       ECO:0000269|PubMed:16611748, ECO:0000269|PubMed:16935860,
CC       ECO:0000269|PubMed:17993579, ECO:0000269|PubMed:18790821,
CC       ECO:0000269|PubMed:18809835, ECO:0000269|PubMed:19241098,
CC       ECO:0000269|PubMed:19253388, ECO:0000269|PubMed:23662938,
CC       ECO:0000269|PubMed:23708187, ECO:0000269|PubMed:24564546,
CC       ECO:0000269|PubMed:26993267, ECO:0000269|PubMed:27864847}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC Ser/Thr
CC       protein kinase family. CDC2/CDKX subfamily. {ECO:0000305}.
CC   -!- CAUTION: It is uncertain whether Met-1 or Met-10 is the initiator.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA61445.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Y15057; CAA75342.1; -; mRNA.
DR   EMBL; AY217744; AAO64440.1; -; mRNA.
DR   EMBL; HQ171445; ADN38258.1; -; mRNA.
DR   EMBL; Z92542; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL109798; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; X89059; CAA61445.1; ALT_FRAME; mRNA.
DR   CCDS; CCDS14186.1; -. [O76039-1]
DR   CCDS; CCDS83458.1; -. [O76039-2]
DR   PIR; S58296; S58296.
DR   RefSeq; NP_001032420.1; NM_001037343.1. [O76039-1]
DR   RefSeq; NP_001310218.1; NM_001323289.1. [O76039-2]
DR   RefSeq; NP_003150.1; NM_003159.2. [O76039-1]
DR   PDB; 4BGQ; X-ray; 2.00 A; A=1-303.
DR   PDBsum; 4BGQ; -.
DR   AlphaFoldDB; O76039; -.
DR   SMR; O76039; -.
DR   BioGRID; 112668; 26.
DR   IntAct; O76039; 23.
DR   MINT; O76039; -.
DR   STRING; 9606.ENSP00000369325; -.
DR   BindingDB; O76039; -.
DR   ChEMBL; CHEMBL1163112; -.
DR   DrugCentral; O76039; -.
DR   iPTMnet; O76039; -.
DR   PhosphoSitePlus; O76039; -.
DR   BioMuta; CDKL5; -.
DR   EPD; O76039; -.
DR   jPOST; O76039; -.
DR   MassIVE; O76039; -.
DR   MaxQB; O76039; -.
DR   PaxDb; O76039; -.
DR   PeptideAtlas; O76039; -.
DR   PRIDE; O76039; -.
DR   ProteomicsDB; 50359; -. [O76039-1]
DR   Antibodypedia; 481; 238 antibodies from 31 providers.
DR   DNASU; 6792; -.
DR   Ensembl; ENST00000379989.6; ENSP00000369325.3; ENSG00000008086.13. [O76039-1]
DR   Ensembl; ENST00000379996.7; ENSP00000369332.3; ENSG00000008086.13. [O76039-1]
DR   Ensembl; ENST00000623535.2; ENSP00000485244.1; ENSG00000008086.13. [O76039-2]
DR   GeneID; 6792; -.
DR   KEGG; hsa:6792; -.
DR   MANE-Select; ENST00000623535.2; ENSP00000485244.1; NM_001323289.2; NP_001310218.1.
DR   UCSC; uc004cym.4; human. [O76039-2]
DR   CTD; 6792; -.
DR   DisGeNET; 6792; -.
DR   GeneCards; CDKL5; -.
DR   HGNC; HGNC:11411; CDKL5.
DR   HPA; ENSG00000008086; Low tissue specificity.
DR   MalaCards; CDKL5; -.
DR   MIM; 300203; gene.
DR   MIM; 300672; phenotype.
DR   neXtProt; NX_O76039; -.
DR   OpenTargets; ENSG00000008086; -.
DR   PharmGKB; PA36218; -.
DR   VEuPathDB; HostDB:ENSG00000008086; -.
DR   eggNOG; KOG0593; Eukaryota.
DR   GeneTree; ENSGT00940000157355; -.
DR   InParanoid; O76039; -.
DR   OMA; YHENLRH; -.
DR   OrthoDB; 398098at2759; -.
DR   PhylomeDB; O76039; -.
DR   TreeFam; TF101032; -.
DR   BRENDA; 2.7.11.22; 2681.
DR   PathwayCommons; O76039; -.
DR   SignaLink; O76039; -.
DR   SIGNOR; O76039; -.
DR   BioGRID-ORCS; 6792; 10 hits in 732 CRISPR screens.
DR   ChiTaRS; CDKL5; human.
DR   GeneWiki; CDKL5; -.
DR   GenomeRNAi; 6792; -.
DR   Pharos; O76039; Tchem.
DR   PRO; PR:O76039; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; O76039; protein.
DR   Bgee; ENSG00000008086; Expressed in frontal pole and 176 other tissues.
DR   ExpressionAtlas; O76039; baseline and differential.
DR   Genevisible; O76039; HS.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0036064; C:ciliary basal body; IDA:UniProtKB.
DR   GO; GO:0097542; C:ciliary tip; IDA:UniProtKB.
DR   GO; GO:0032839; C:dendrite cytoplasm; ISS:BHF-UCL.
DR   GO; GO:0044294; C:dendritic growth cone; ISS:BHF-UCL.
DR   GO; GO:0098978; C:glutamatergic synapse; IDA:SynGO.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:HGNC-UCL.
DR   GO; GO:0005524; F:ATP binding; IDA:HGNC-UCL.
DR   GO; GO:0004693; F:cyclin-dependent protein serine/threonine kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0016301; F:kinase activity; IDA:MGI.
DR   GO; GO:0004672; F:protein kinase activity; IDA:HGNC-UCL.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:ProtInc.
DR   GO; GO:0031267; F:small GTPase binding; ISS:BHF-UCL.
DR   GO; GO:0001764; P:neuron migration; ISS:BHF-UCL.
DR   GO; GO:0045773; P:positive regulation of axon extension; ISS:BHF-UCL.
DR   GO; GO:0050775; P:positive regulation of dendrite morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; ISS:BHF-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:HGNC-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; IBA:GO_Central.
DR   GO; GO:1902017; P:regulation of cilium assembly; IMP:UniProtKB.
DR   GO; GO:0050773; P:regulation of dendrite development; ISS:BHF-UCL.
DR   GO; GO:0099175; P:regulation of postsynapse organization; IDA:SynGO.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell projection;
KW   Chromosomal rearrangement; Cytoplasm; Cytoskeleton; Disease variant;
KW   Epilepsy; Intellectual disability; Kinase; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Reference proteome; Serine/threonine-protein kinase;
KW   Transferase.
FT   CHAIN           1..960
FT                   /note="Cyclin-dependent kinase-like 5"
FT                   /id="PRO_0000085826"
FT   DOMAIN          13..297
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          300..349
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          382..566
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          646..834
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          848..960
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        317..349
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        382..406
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        431..551
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        552..566
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        671..706
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        724..754
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        766..780
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        794..817
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        848..890
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        912..952
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        135
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         19..27
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         42
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         407
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         479
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         720
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         761
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   VAR_SEQ         905..960
FT                   /note="GQMDPGWHVSSVTRSATEGPSYSEQLGAKSGPNGHPYNRTNRSRMPNLNDLK
FT                   ETAL -> DGGCDGRRQRHHSGPQDRRFMLRTTEQQGEYFCCGDPKKPHTPCVPNRALH
FT                   RPISSPAPYPVLQVRGTSMCPTLQVRGTDAFSCPTQQSGFSFFVRHVMREALIHRAQVN
FT                   QAALLTYHENAALTGK (in isoform 2)"
FT                   /evidence="ECO:0000269|PubMed:21748340"
FT                   /id="VSP_060755"
FT   VARIANT         40
FT                   /note="A -> V (in DEE2; causes mislocalization of the
FT                   protein in the cytoplasm; dbSNP:rs122460159)"
FT                   /evidence="ECO:0000269|PubMed:17993579,
FT                   ECO:0000269|PubMed:18790821"
FT                   /id="VAR_058022"
FT   VARIANT         72
FT                   /note="I -> N (in DEE2; dbSNP:rs62641235)"
FT                   /evidence="ECO:0000269|PubMed:16015284"
FT                   /id="VAR_058023"
FT   VARIANT         72
FT                   /note="I -> T (in DEE2; dbSNP:rs62641235)"
FT                   /evidence="ECO:0000269|PubMed:19241098"
FT                   /id="VAR_058024"
FT   VARIANT         127
FT                   /note="H -> R (in DEE2; dbSNP:rs267608468)"
FT                   /evidence="ECO:0000269|PubMed:19241098"
FT                   /id="VAR_058025"
FT   VARIANT         145
FT                   /note="H -> Y (in DEE2; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:23708187"
FT                   /id="VAR_078625"
FT   VARIANT         152
FT                   /note="C -> F (in DEE2; affect activity; causes
FT                   mislocalization of the protein in the cytoplasm;
FT                   dbSNP:rs122460157)"
FT                   /evidence="ECO:0000269|PubMed:15499549,
FT                   ECO:0000269|PubMed:16935860"
FT                   /id="VAR_023560"
FT   VARIANT         175
FT                   /note="R -> S (in DEE2; affect activity; does not affect
FT                   the cellular distribution of the protein;
FT                   dbSNP:rs61749700)"
FT                   /evidence="ECO:0000269|PubMed:15499549,
FT                   ECO:0000269|PubMed:16935860"
FT                   /id="VAR_023561"
FT   VARIANT         178
FT                   /note="R -> P (in DEE2; dbSNP:rs267606715)"
FT                   /evidence="ECO:0000269|PubMed:18809835"
FT                   /id="VAR_058026"
FT   VARIANT         178
FT                   /note="R -> Q (in DEE2; dbSNP:rs267606715)"
FT                   /evidence="ECO:0000269|PubMed:23662938,
FT                   ECO:0000269|PubMed:23708187, ECO:0000269|PubMed:24564546"
FT                   /id="VAR_071103"
FT   VARIANT         178
FT                   /note="R -> W (in DEE2; dbSNP:rs267608493)"
FT                   /evidence="ECO:0000269|PubMed:26993267"
FT                   /id="VAR_078712"
FT   VARIANT         180
FT                   /note="P -> L (in DEE2; dbSNP:rs61749704)"
FT                   /evidence="ECO:0000269|PubMed:16611748"
FT                   /id="VAR_037635"
FT   VARIANT         182
FT                   /note="L -> P (in DEE2)"
FT                   /evidence="ECO:0000269|PubMed:23708187"
FT                   /id="VAR_078626"
FT   VARIANT         196
FT                   /note="S -> L (in DEE2; dbSNP:rs267608501)"
FT                   /evidence="ECO:0000269|PubMed:27864847"
FT                   /id="VAR_078219"
FT   VARIANT         207
FT                   /note="G -> E (in DEE2)"
FT                   /evidence="ECO:0000269|PubMed:23708187"
FT                   /id="VAR_078627"
FT   VARIANT         220
FT                   /note="L -> P (in DEE2; causes mislocalization of the
FT                   protein in the cytoplasm; dbSNP:rs267608511)"
FT                   /evidence="ECO:0000269|PubMed:17993579,
FT                   ECO:0000269|PubMed:18790821"
FT                   /id="VAR_058027"
FT   VARIANT         288
FT                   /note="T -> I (in DEE2; dbSNP:rs267606713)"
FT                   /evidence="ECO:0000269|PubMed:18809835"
FT                   /id="VAR_058028"
FT   VARIANT         291
FT                   /note="C -> Y (in DEE2; dbSNP:rs267606714)"
FT                   /evidence="ECO:0000269|PubMed:18809835"
FT                   /id="VAR_058029"
FT   VARIANT         368
FT                   /note="N -> H (in a colorectal cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036578"
FT   VARIANT         374
FT                   /note="A -> T (in a metastatic melanoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041997"
FT   VARIANT         399
FT                   /note="N -> T (in DEE2; dbSNP:rs267608611)"
FT                   /evidence="ECO:0000269|PubMed:19253388"
FT                   /id="VAR_058030"
FT   VARIANT         444
FT                   /note="R -> C (in dbSNP:rs61753977)"
FT                   /evidence="ECO:0000269|PubMed:16015284"
FT                   /id="VAR_058031"
FT   VARIANT         574
FT                   /note="P -> Q (in an ovarian serous carcinoma sample;
FT                   somatic mutation; dbSNP:rs199897804)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041998"
FT   VARIANT         581
FT                   /note="H -> Y (in DEE2; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:23708187"
FT                   /id="VAR_078628"
FT   VARIANT         647
FT                   /note="P -> L (probable disease-associated variant found in
FT                   a patient with autism spectrum disorder)"
FT                   /evidence="ECO:0000269|PubMed:25969726"
FT                   /id="VAR_078713"
FT   VARIANT         718
FT                   /note="V -> M (in DEE2; dbSNP:rs267608653)"
FT                   /evidence="ECO:0000269|PubMed:18790821,
FT                   ECO:0000269|PubMed:26993267"
FT                   /id="VAR_058032"
FT   VARIANT         726..960
FT                   /note="Missing (in DEE2)"
FT                   /evidence="ECO:0000269|PubMed:26993267"
FT                   /id="VAR_078714"
FT   VARIANT         734
FT                   /note="T -> A (in dbSNP:rs55803460)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041999"
FT   VARIANT         791
FT                   /note="Q -> P (in dbSNP:rs35478150)"
FT                   /evidence="ECO:0000269|PubMed:12736870,
FT                   ECO:0000269|PubMed:15499549, ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:19241098"
FT                   /id="VAR_023562"
FT   VARIANT         793
FT                   /note="V -> A (in DEE2; unknown pathological significance;
FT                   dbSNP:rs62643617)"
FT                   /evidence="ECO:0000269|PubMed:16611748"
FT                   /id="VAR_037636"
FT   VARIANT         855..960
FT                   /note="Missing (probable disease-associated variant found
FT                   in a patient with infatile spasms)"
FT                   /evidence="ECO:0000269|PubMed:23708187"
FT                   /id="VAR_078629"
FT   VARIANT         858
FT                   /note="R -> C (in DEE2; unknown pathological significance;
FT                   dbSNP:rs773760466)"
FT                   /evidence="ECO:0000269|PubMed:23708187"
FT                   /id="VAR_078630"
FT   CONFLICT        339..340
FT                   /note="HR -> GT (in Ref. 5; CAA61445)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        541
FT                   /note="L -> W (in Ref. 5; CAA61445)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        731..764
FT                   /note="Missing (in Ref. 5; CAA61445)"
FT                   /evidence="ECO:0000305"
FT   TURN            10..12
FT                   /evidence="ECO:0007829|PDB:4BGQ"
FT   STRAND          13..24
FT                   /evidence="ECO:0007829|PDB:4BGQ"
FT   STRAND          26..32
FT                   /evidence="ECO:0007829|PDB:4BGQ"
FT   TURN            33..35
FT                   /evidence="ECO:0007829|PDB:4BGQ"
FT   STRAND          38..43
FT                   /evidence="ECO:0007829|PDB:4BGQ"
FT   HELIX           55..66
FT                   /evidence="ECO:0007829|PDB:4BGQ"
FT   STRAND          75..81
FT                   /evidence="ECO:0007829|PDB:4BGQ"
FT   STRAND          84..90
FT                   /evidence="ECO:0007829|PDB:4BGQ"
FT   STRAND          93..95
FT                   /evidence="ECO:0007829|PDB:4BGQ"
FT   HELIX           96..102
FT                   /evidence="ECO:0007829|PDB:4BGQ"
FT   HELIX           109..128
FT                   /evidence="ECO:0007829|PDB:4BGQ"
FT   HELIX           138..140
FT                   /evidence="ECO:0007829|PDB:4BGQ"
FT   STRAND          141..143
FT                   /evidence="ECO:0007829|PDB:4BGQ"
FT   STRAND          149..151
FT                   /evidence="ECO:0007829|PDB:4BGQ"
FT   HELIX           180..183
FT                   /evidence="ECO:0007829|PDB:4BGQ"
FT   HELIX           191..206
FT                   /evidence="ECO:0007829|PDB:4BGQ"
FT   HELIX           216..227
FT                   /evidence="ECO:0007829|PDB:4BGQ"
FT   HELIX           232..240
FT                   /evidence="ECO:0007829|PDB:4BGQ"
FT   HELIX           242..244
FT                   /evidence="ECO:0007829|PDB:4BGQ"
FT   HELIX           258..262
FT                   /evidence="ECO:0007829|PDB:4BGQ"
FT   TURN            263..265
FT                   /evidence="ECO:0007829|PDB:4BGQ"
FT   HELIX           268..277
FT                   /evidence="ECO:0007829|PDB:4BGQ"
FT   HELIX           282..284
FT                   /evidence="ECO:0007829|PDB:4BGQ"
FT   HELIX           288..292
FT                   /evidence="ECO:0007829|PDB:4BGQ"
FT   HELIX           295..298
FT                   /evidence="ECO:0007829|PDB:4BGQ"
FT   VARIANT         O76039-1:923
FT                   /note="R -> C (in dbSNP:rs267608664)"
FT                   /evidence="ECO:0000269|PubMed:19241098"
FT                   /id="VAR_083796"
FT   VARIANT         O76039-1:994
FT                   /note="G -> R (in DEE2; unknown pathological significance;
FT                   dbSNP:rs866859766)"
FT                   /evidence="ECO:0000269|PubMed:27864847"
FT                   /id="VAR_083797"
FT   VARIANT         O76039-1:999
FT                   /note="V -> M (in dbSNP:rs35693326)"
FT                   /id="VAR_083798"
FT   VARIANT         O76039-1:1023
FT                   /note="E -> G (in dbSNP:rs34166184)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_083799"
SQ   SEQUENCE   960 AA;  107519 MW;  6E955E0B40DBC1B8 CRC64;
     MKIPNIGNVM NKFEILGVVG EGAYGVVLKC RHKETHEIVA IKKFKDSEEN EEVKETTLRE
     LKMLRTLKQE NIVELKEAFR RRGKLYLVFE YVEKNMLELL EEMPNGVPPE KVKSYIYQLI
     KAIHWCHKND IVHRDIKPEN LLISHNDVLK LCDFGFARNL SEGNNANYTE YVATRWYRSP
     ELLLGAPYGK SVDMWSVGCI LGELSDGQPL FPGESEIDQL FTIQKVLGPL PSEQMKLFYS
     NPRFHGLRFP AVNHPQSLER RYLGILNSVL LDLMKNLLKL DPADRYLTEQ CLNHPTFQTQ
     RLLDRSPSRS AKRKPYHVES STLSNRNQAG KSTALQSHHR SNSKDIQNLS VGLPRADEGL
     PANESFLNGN LAGASLSPLH TKTYQASSQP GSTSKDLTNN NIPHLLSPKE AKSKTEFDFN
     IDPKPSEGPG TKYLKSNSRS QQNRHSFMES SQSKAGTLQP NEKQSRHSYI DTIPQSSRSP
     SYRTKAKSHG ALSDSKSVSN LSEARAQIAE PSTSRYFPSS CLDLNSPTSP TPTRHSDTRT
     LLSPSGRNNR NEGTLDSRRT TTRHSKTMEE LKLPEHMDSS HSHSLSAPHE SFSYGLGYTS
     PFSSQQRPHR HSMYVTRDKV RAKGLDGSLS IGQGMAARAN SLQLLSPQPG EQLPPEMTVA
     RSSVKETSRE GTSSFHTRQK SEGGVYHDPH SDDGTAPKEN RHLYNDPVPR RVGSFYRVPS
     PRPDNSFHEN NVSTRVSSLP SESSSGTNHS KRQPAFDPWK SPENISHSEQ LKEKEKQGFF
     RSMKKKKKKS QTVPNSDSPD LLTLQKSIHS ASTPSSRPKE WRPEKISDLQ TQSQPLKSLR
     KLLHLSSASN HPASSDPRFQ PLTAQQTKNS FSEIRIHPLS QASGGSSNIR QEPAPKGRPA
     LQLPGQMDPG WHVSSVTRSA TEGPSYSEQL GAKSGPNGHP YNRTNRSRMP NLNDLKETAL
//
